The FDA has approved once-daily oral Rasonque (daraxonrasib) for adults with metastatic pancreatic ductal adenocarcinoma (PDAC) after prior systemic therapy or for those not eligible for multiagent therapy, backed by the Phase III RASolute 302 trial in 500 patients. In RASolute 302, daraxonrasib doubled median overall survival versus physician’s-choice chemotherapy, 13.2 months vs. 6.7 months, with median progression-free survival of 7.2 months in the overall population and 7.3 months in RAS G12-mutant disease.

Why It Matters To Oncology

• Metastatic PDAC is a malignant neoplasm with high unmet need, and experts described these data as the first demonstration that something beyond chemotherapy improves survival in this setting.

• The benefit was reported in both RAS G12-variant tumors and the all-comer population, potentially broadening clinical relevance beyond a narrow biomarker-defined subgroup.

• As an oral RAS inhibitor, Rasonque may also shift treatment sequencing discussions in second-line PDAC and intensify interest in RAS-directed drug discovery across GI oncology.

The Financials

• Revolution Medicines secured approval less than five months after first disclosing the pivotal data and just one month after FDA acceptance of the application.

• The drug also received a Commissioner’s National Priority Voucher, with approval arriving about 6.5 months ahead of the formal PDUFA date.

• Rapid review and a potentially practice-changing label could strengthen the company’s competitive position in the emerging RAS inhibitor market.

What They're Saying

• FDA Oncology Center of Excellence director Angelo de Claro said the drug showed “unprecedented results in an area of high unmet need.”

• A PDAC expert cited by FirstWord called the survival results “very gratifying” because it was “the first time ever” a therapy beyond chemotherapy improved survival in PDAC.

• In a recent physician survey, 94% of respondents viewed the RASolute 302 data as practice-changing for second-line PDAC, with many also expressing willingness to prescribe off-label in first-line disease.

What's Next

• Revolution is advancing additional PDAC studies in frontline and resectable disease, aiming to move daraxonrasib earlier in treatment.

• Outside pancreas cancer, the company is running the Phase III RASolve 301 study in previously treated non–small-cell lung cancer and a Phase I/II platform study in colorectal cancer.

• Combination work is underway with ivonescimab and PRMT5 inhibitors, while an early study of daraxonrasib plus zoldonrasib showed a 50% overall response rate, 97% disease control rate, and 9.6-month median progression-free survival in 30 previously treated KRAS G12D-mutant solid tumors.